ZRANB1 overexpression was associated with poorer survival in patients with HCC, and there was a significant positive correlation between the expressions of ZRANB1 and LOXL2 in clinical HCC specimens, which can regulate the expression of LOXL2 through specific protein 1 (SP1). This evidence concerns the gene LOXL2 and hepatocellular carcinoma.